RxDoctor Payments Data

Anjan Ghosh, MD

Interventional Pain Medicine · Trinity, FLNPI 1124089354

Payments from drug & device makers

$606in general payments, 2019–2025

Across 24 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$190
  • Collegium Pharmaceutical, Inc.$161
  • Abbott$122
  • Biodelivery Sciences International, Inc.$66
  • Scilex Pharmaceuticals Inc.$33
  • Zyla Life Sciences, Inc.$23
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific2$190
Collegium Pharmaceutical, Inc.9$161
Abbott5$122
Biodelivery Sciences International, Inc.4$66
Scilex Pharmaceuticals Inc.2$33
Zyla Life Sciences, Inc.1$23
Sentynl Therapeutics, Inc.1$12

How this compares

$606 in reported general payments places this provider in the 15th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$284,236
Medicare patients
257
Services billed
5,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate188$129,579
RelistorMethylnaltrexone Bromide30$77,108
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,588$60,460
Oxycodone Hcl2,052$49,565
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,807$46,746
MovantikNaloxegol Oxalate90$45,844
Morphine Sulfate ErMorphine Sulfate1,433$43,415
Nucynta ErTapentadol Hcl13$31,811
Diclofenac Epolamine44$24,074
NucyntaTapentadol Hcl13$21,659
Fentanyl176$16,698
LyricaPregabalin15$12,994
BelbucaBuprenorphine Hcl13$12,744
Tizanidine Hcl924$10,721
Lidocaine94$8,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Nucynta, Belbuca$161$195,793227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →